Company intelligence / Profile preview

Ocelot

San Diego, California, United Statesocelotbio.com ↗

Ownership: Public · OACAU
Employees: ~14
Development stage: Other

Overview

Ocelot Bio’s lead candidate, OCE-205, has shown activity and safety in Phase 1 clinical trials and is currently in Phase 2 for hepatorenal syndrome with acute kidney injury (HRS-AKI). The FDA has granted OCE-205 Orphan Drug Designation for this indication. A second program for ascites is in preclinical development. Data presented at AASLD demonstrated pharmacodynamic activity and safety in healthy volunteers[5][7].

Therapeutic areas: NephrologyCardiovascularGastroenterology
Modalities: Synthetic peptideSmall molecule
Industry: Biotech

Beyond the preview

Go deeper on Ocelot.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ocelot.

Explore the full profile